Table 1 Patient demographics, disease characteristics, cell counts, CMV and EBV DNA count at baseline
Placebo (n = 50) | Tofacitinib 2 mg BID (n = 49) | Tofacitinib 5 mg BID (n = 49) | Tofacitinib 15 mg BID (n = 49) | |
|---|---|---|---|---|
Mean age, years (SD) | 43.9 (13.0) | 45.7 (13.8) | 44.0 (12.6) | 43.6 (15.6) |
Male, n (%) | 36 (72.0) | 29 (59.2) | 29 (59.2) | 31 (63.2) |
White, n (%) | 41 (82.0) | 36 (73.5) | 42 (85.7) | 40 (81.6) |
Mean weight, kg (SD) | 89.6 (23.9) | 89.6 (23.0) | 92.2 (23.5) | 93.1 (29.7) |
Mean PASI score (SD) | 21.5 (7.1) | 21.5 (6.7) | 21.2 (8.1) | 22.6 (10.3) |
Mean BSA, % (SD) | 29.8 (13.5) | 29.8 (13.4) | 30.1 (17.0) | 31.9 (18.8) |
PGA, n (%): | ||||
Mild | 6 (12.0) | 8 (16.3) | 11 (22.4) | 9 (18.8) |
Moderate | 41 (82.0) | 39 (79.6) | 33 (67.3) | 33 (68.8) |
Severe | 3 (6.0) | 2 (4.1) | 5 (10.2) | 6 (12.5) |
Median cell counts, cells/mm3 (Q25, Q75): | ||||
T (CD3+) | 1310 (982, 1517) | 1115 (894, 1455) | 1206 (1047, 1578) | 1162 (935, 1510) |
TH (CD3+/CD4+) | 802 (615, 975) | 730 (572, 931) | 868 (637, 998) | 744 (597, 950) |
TC (CD3+/CD8+) | 431 (287, 570) | 331 (246, 498) | 392 (264, 501) | 386 (292, 539) |
B (CD19+) | 195 (134, 304) | 241 (136, 322) | 198 (163, 300) | 247 (143, 343) |
NK (CD16+/CD56+) | 159 (93, 188) | 135 (91, 214) | 130 (95, 207) | 152 (97, 216) |
Median CMV viral load, copies/500 ng total DNA (Q25, Q75) | 0 (0.00, 0.00) | 0 (0.00, 0.00) | 0 (0.00, 0.00) | 0 (0.00, 0.00) |
Median EBV viral load, copies/500 ng total DNA (Q25, Q75) | 0 (0.00, 1.30) | 0 (0.00, 0.95) | 0 (0.00, 1.00) | 0 (0.00, 0.85) |
Median CRP, mg/L (Q25, Q75) | 1.84 (0.83, 4.41) | 2.54 (1.13, 7.79) | 1.92 (1.02, 5.84) | 3.14 (0.92, 7.86) |